TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07531251: Clinical Trial in Patients With Barth Syndrome- 4TAZPower

Sponsor: Stealth BioTherapeutics Inc. · Phase: PHASE4 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 48 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$584,320

Rescue Site Savings

+$398,400

Unlock Full NCT07531251 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07531251 Rescue Dossier →